224 related articles for article (PubMed ID: 30464690)
1. Patients with non-small-cell lung cancer harbouring a
Auliac JB; Bayle S; Vergnenegre A; Le Caer H; Falchero L; Gervais R; Doubre H; Vinas F; Marin B; Chouaid C
Curr Oncol; 2018 Oct; 25(5):e398-e402. PubMed ID: 30464690
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study.
Couraud S; Barlesi F; Fontaine-Deraluelle C; Debieuvre D; Merlio JP; Moreau L; Beau-Faller M; Veillon R; Mosser J; Al Freijat F; Bringuier PP; Léna H; Ouafik L; Westeel V; Morel A; Audigier-Valette C; Missy P; Langlais A; Morin F; Souquet PJ; Planchard D;
Eur J Cancer; 2019 Jul; 116():86-97. PubMed ID: 31181537
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations.
Tissot C; Couraud S; Tanguy R; Bringuier PP; Girard N; Souquet PJ
Lung Cancer; 2016 Jan; 91():23-8. PubMed ID: 26711930
[TBL] [Abstract][Full Text] [Related]
4. Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02-14 Study).
Auliac JB; Monnet I; Dubos-Arvis C; Chiappa AM; Baize N; Bota S; Vergnenegre A; Doubre H; Locher C; Bizieux A; Robinet G; Chouaid C
Target Oncol; 2017 Dec; 12(6):833-838. PubMed ID: 28762087
[TBL] [Abstract][Full Text] [Related]
5. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.
Cardarella S; Ogino A; Nishino M; Butaney M; Shen J; Lydon C; Yeap BY; Sholl LM; Johnson BE; Jänne PA
Clin Cancer Res; 2013 Aug; 19(16):4532-40. PubMed ID: 23833300
[TBL] [Abstract][Full Text] [Related]
6. Natural Disease History, Outcomes, and Co-mutations in a Series of Patients With BRAF-Mutated Non-small-cell Lung Cancer.
Myall NJ; Henry S; Wood D; Neal JW; Han SS; Padda SK; Wakelee HA
Clin Lung Cancer; 2019 Mar; 20(2):e208-e217. PubMed ID: 30442523
[TBL] [Abstract][Full Text] [Related]
7. Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer.
Horn L; Bauml J; Forde PM; Davis KL; Myall NJ; Sasane M; Dalal A; Culver K; Wozniak AJ; Baik CS; Mutebi A; Zhang P; Wakelee HA; Johnson BE
Lung Cancer; 2019 Feb; 128():74-90. PubMed ID: 30642457
[TBL] [Abstract][Full Text] [Related]
8. Dabrafenib plus trametinib in patients with previously untreated BRAF
Planchard D; Smit EF; Groen HJM; Mazieres J; Besse B; Helland Å; Giannone V; D'Amelio AM; Zhang P; Mookerjee B; Johnson BE
Lancet Oncol; 2017 Oct; 18(10):1307-1316. PubMed ID: 28919011
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic characteristics and outcomes of Chinese patients with non-small-cell lung cancer and BRAF mutation.
Ding X; Zhang Z; Jiang T; Li X; Zhao C; Su B; Zhou C
Cancer Med; 2017 Mar; 6(3):555-562. PubMed ID: 28135039
[TBL] [Abstract][Full Text] [Related]
10. FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring
Odogwu L; Mathieu L; Blumenthal G; Larkins E; Goldberg KB; Griffin N; Bijwaard K; Lee EY; Philip R; Jiang X; Rodriguez L; McKee AE; Keegan P; Pazdur R
Oncologist; 2018 Jun; 23(6):740-745. PubMed ID: 29438093
[TBL] [Abstract][Full Text] [Related]
11. BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy.
Wiesweg M; Preuß C; Roeper J; Metzenmacher M; Eberhardt W; Stropiep U; Wedeken K; Reis H; Herold T; Darwiche K; Aigner C; Stuschke M; Schildhaus HU; Schmid KW; Falk M; Heukamp L; Tiemann M; Griesinger F; Schuler M
Eur J Cancer; 2021 May; 149():211-221. PubMed ID: 33872981
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018.
Guisier F; Dubos-Arvis C; Viñas F; Doubre H; Ricordel C; Ropert S; Janicot H; Bernardi M; Fournel P; Lamy R; Pérol M; Dauba J; Gonzales G; Falchero L; Decroisette C; Assouline P; Chouaid C; Bylicki O
J Thorac Oncol; 2020 Apr; 15(4):628-636. PubMed ID: 31945494
[TBL] [Abstract][Full Text] [Related]
13. Targeting
Baik CS; Myall NJ; Wakelee HA
Oncologist; 2017 Jul; 22(7):786-796. PubMed ID: 28487464
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and breakdown of non-small cell lung cancer BRAF driver mutations in a large UK cohort.
Lim GHT; Balbi KJ; Poskitt B; Bennett P; Moore DA
Lung Cancer; 2022 Nov; 173():71-74. PubMed ID: 36156323
[TBL] [Abstract][Full Text] [Related]
15. Non-Small Cell Lung Cancer Patients Harboring HER2 Mutations: Clinical Characteristics and Management in a Real-Life Setting. Cohort HER2 EXPLORE GFPC 02-14.
Auliac JB; Dô P; Bayle S; Doubre H; Vinas F; Letreut J; Falchero L; Hauss PA; Thomas P; Chouaid C
Adv Ther; 2019 Aug; 36(8):2161-2166. PubMed ID: 31154630
[TBL] [Abstract][Full Text] [Related]
16. BRAF V600E mutations: a series of case reports in patients with non-small cell lung cancer.
Goldman JM; Gray JE
Cancer Genet; 2015 Jun; 208(6):351-4. PubMed ID: 26066373
[TBL] [Abstract][Full Text] [Related]
17. Clinical Characteristics, Co-Mutations, and Treatment Outcomes in Advanced Non-Small-Cell Lung Cancer Patients With the BRAF-V600E Mutation.
Qu J; Shen Q; Li Y; Kalyani FS; Liu L; Zhou J; Zhou J
Front Oncol; 2022; 12():911303. PubMed ID: 35814395
[TBL] [Abstract][Full Text] [Related]
18. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).
Barlesi F; Mazieres J; Merlio JP; Debieuvre D; Mosser J; Lena H; Ouafik L; Besse B; Rouquette I; Westeel V; Escande F; Monnet I; Lemoine A; Veillon R; Blons H; Audigier-Valette C; Bringuier PP; Lamy R; Beau-Faller M; Pujol JL; Sabourin JC; Penault-Llorca F; Denis MG; Lantuejoul S; Morin F; Tran Q; Missy P; Langlais A; Milleron B; Cadranel J; Soria JC; Zalcman G;
Lancet; 2016 Apr; 387(10026):1415-1426. PubMed ID: 26777916
[TBL] [Abstract][Full Text] [Related]
19. V600E BRAF versus Non-V600E BRAF Mutated Lung Adenocarcinomas: Cytomorphology, Histology, Coexistence of Other Driver Mutations and Patient Characteristics.
Salimian KJ; Fazeli R; Zheng G; Ettinger D; Maleki Z
Acta Cytol; 2018; 62(2):79-84. PubMed ID: 29320776
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of first-line immune checkpoint inhibitors in patients with advanced NSCLC with KRAS, MET, FGFR, RET, BRAF, and HER2 alterations.
Uehara Y; Watanabe K; Hakozaki T; Yomota M; Hosomi Y
Thorac Cancer; 2022 Jun; 13(11):1703-1711. PubMed ID: 35491960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
